Publications by authors named "Karen D Price"

Harnessing the immune system to kill tumors has been revolutionary and, as a result, has had an enormous benefit for patients in extending life and resulting in effective cures in some. However, activation of the immune system can come at the cost of undesirable adverse events such as cytokine release syndrome, immune-related adverse events, on-target/off-tumor toxicity, neurotoxicity and tumor lysis syndrome, which are safety risks that can be challenging to assess non-clinically. This article provides a review of the biology and mechanisms that can result in immune-mediated adverse effects and describes industry approaches using in vitro and in vivo models to aid in the nonclinical safety risk assessments for immune-oncology modalities.

View Article and Find Full Text PDF
Article Synopsis
  • - Immune checkpoint inhibitors (ICIs) are effective cancer treatments but can cause unique liver injuries known as immune-mediated liver injury caused by checkpoint inhibitors (ILICI), which differ from typical drug-induced liver injuries.
  • - There is a lack of standardized best practices for managing ILICI during drug development, even though awareness and guidelines for these immune-related adverse effects are increasing.
  • - This publication provides recommendations for monitoring, diagnosing, and managing ILICI in clinical trials, focusing on best practices related to liver test monitoring, detection, causality assessment, and treatment protocols.
View Article and Find Full Text PDF

Functional innate immune assessments, including phagocytosis and respiratory burst, are at the forefront of immunotoxicology evaluation in pre-clinical animal species. Although in the clinic and in academic science, phagocytosis, and respiratory burst assessments have been reported for over two decades, the implementation of phagocytosis and respiratory burst analyses in toxicology safety programs is just recently gaining publicity. Discussed herein are general methods, both microtiter plate-based and flow cytometric-based, for assessing phagocytosis and respiratory burst in pre-clinical species including mouse, rat, dog, and monkey.

View Article and Find Full Text PDF

A multinational pharmaceutical and biotechnology company survey was conducted to gain a better understanding of the use and value of the tissue cross-reactivity (TCR) assay in the development of biotherapeutic molecules. The majority of the molecules did not use TCR data as the only basis for determining species selection for toxicity studies (73%). For 95% of the molecules, the TCR data had no impact on the development strategy.

View Article and Find Full Text PDF
Article Synopsis
  • Non-human primates (NHP) are vital for studying drug effects and safety to benefit humans with critical health needs.
  • Understanding the health and normal microorganisms of NHP is crucial for collecting accurate data and ensuring effective research outcomes.
  • The publication discusses insights from various experts on common and emerging infections in NHP, focusing on their impact on immune response and the implications for treatment.
View Article and Find Full Text PDF

Opportunistic infections (OIs) during the course of non-clinical toxicity studies can serve as a clinical indicator of immunosuppression. In monkeys, severity may be magnified since the possibility for fecal-oral and cage-to-cage transmission of bacteria exists, reserve capacity is low, and clinical signs of infection are not easily detected until the infectious process is well underway. This review summarizes a case study presented at the HESI-ILSI ITC-Sponsored workshop on Naturally Occurring Infections in Non-human Primates and Immunotoxicity Implications.

View Article and Find Full Text PDF

Systemic lupus erythematosus (SLE) is a multiorgan autoimmune disease affecting 40-50/100,000 Americans. Although most of the research on pathogenic antibodies focuses on antigenic specificity, there is increasing evidence that specific immunoglobulin idiotypes may mediate lupus nephritis independent of autoantigen specificity. In previous work, our laboratory characterized a set of nephritogenic monoclonal antibodies with substantial idiotypic cross-reactivity, produced by the spontaneous SLE model (SWR x NZB)F(1) (SNF(1)), termed Id(LN)F(1).

View Article and Find Full Text PDF